For nearly half of patients with myelodysplastic syndromes, results could change clinical care<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 16, 2023 (HealthDay News) — Implementing the International Prognostic Scoring System-Molecular (IPSS-M) in clinical practice could impact clinical management for nearly half of patients with myelodysplastic syndromes (MDS), according to a study published online May 18 in Frontiers in Oncology<\/em>.<\/p>\n Irene Zamanillo, from University Hospital 12 Octubre in Madrid, and colleagues analyzed clinical, cytogenetic, and molecular data from 166 MDS patients. IPSS-Revised and IPSS-M were calculated and survival was assessed.<\/p>\n The researchers found that 86.1 percent of patients had at least one genetic alteration, including most frequently SF3B1<\/em> (25.9 percent), DNMT3A<\/em> (16.8 percent), and ASXL1<\/em> (14.4 percent). Nearly half of patients (48.2 percent) were restratified with IPSS-M, including 16.9 percent who were downgraded and 31.3 percent who were upgraded. For overall survival, IPSS-M improved outcome prediction with a Harrell s c-index of 0.680 versus 0.626, and 0.801 versus 0.757 for leukemia-free survival. For nearly one-quarter of patients (22.2 percent), the reclassification of the IPSS-M could potentially affect clinical management, with 17.4 percent eligible for treatment intensification and 4.8 percent for treatment reduction.<\/p>\n “IPSS-M implementation in clinical practice could imply different treatment approaches in a significant number of patients,” the authors write. “Our work validates IPSS-M in an external cohort and confirms its applicability in a real-life setting.”<\/p>\n